Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02952508
What this trial is testing

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Who this might be right for
Waldenstrom MacroglobulinemiaMultiple MyelomaChronic Lymphocytic Leukemia+6 more
Cellectar Biosciences, Inc. 120
Testing effectiveness (Phase 2)Study completedNCT00918333
What this trial is testing

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+25 more
Mayo Clinic 124
Early research (Phase 1)Study completedNCT00002818
What this trial is testing

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

Who this might be right for
Drug/Agent Toxicity by Tissue/OrganLeukemiaLymphoma+1 more
Virginia Commonwealth University 15
Early research (Phase 1)Ended earlyNCT04975399
What this trial is testing

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 26
Early research (Phase 1)Study completedNCT00962507
What this trial is testing

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
LymphomaMultiple Myeloma and Plasma Cell Neoplasm
City of Hope Medical Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT07477912
What this trial is testing

Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma Refractory
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 30
Early research (Phase 1)Study completedNCT03263637
What this trial is testing

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Who this might be right for
Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+8 more
AstraZeneca 44
Testing effectiveness (Phase 2)UnknownNCT01754402
What this trial is testing

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Who this might be right for
Multiple Myeloma
Cristina Gasparetto 56
Testing effectiveness (Phase 2)Ended earlyNCT00538824
What this trial is testing

Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Weill Medical College of Cornell University 5
Early research (Phase 1)Looking for participantsNCT07529782
What this trial is testing

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Other Plasma Cell Neoplasms
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 15
Early research (Phase 1)Study completedNCT02616640
What this trial is testing

Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 114
Large-scale testing (Phase 3)Active Not RecruitingNCT05552976
What this trial is testing

Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb 606
Large-scale testing (Phase 3)Study completedNCT00005805
What this trial is testing

St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer

Who this might be right for
Chronic Myeloproliferative DisordersFatigueLeukemia+5 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Looking for participantsNCT04162353
What this trial is testing

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple MyelomaPlasmacytoid; Lymphoma
iCell Gene Therapeutics 12
Testing effectiveness (Phase 2)Ended earlyNCT03256045
What this trial is testing

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
University of Washington 9
Testing effectiveness (Phase 2)Study completedNCT04445701
What this trial is testing

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Arch Oncology 10
Large-scale testing (Phase 3)WithdrawnNCT06232707
What this trial is testing

Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene
Early research (Phase 1)Study completedNCT02189343
What this trial is testing

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 16
Testing effectiveness (Phase 2)Study completedNCT03430011
What this trial is testing

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene 165
Early research (Phase 1)Active Not RecruitingNCT03399799
What this trial is testing

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 279
Next Page